Fig. 1From: PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in ChinaProbability of patients achieving pCR in overall cohort. a HR status. b ER status. c PR statusBack to article page